539 related articles for article (PubMed ID: 36115290)
1. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
[TBL] [Abstract][Full Text] [Related]
2. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
[TBL] [Abstract][Full Text] [Related]
3. Application of immune checkpoint inhibitors in colorectal cancer.
Wang L; Huang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736
[TBL] [Abstract][Full Text] [Related]
4. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability.
Ratovomanana T; Nicolle R; Cohen R; Diehl A; Siret A; Letourneur Q; Buhard O; Perrier A; Guillerm E; Coulet F; Cervera P; Benusiglio P; Labrèche K; Colle R; Collura A; Despras E; Le Rouzic P; Renaud F; Cros J; Alentorn A; Touat M; Ayadi M; Bourgoin P; Prunier C; Tournigand C; Fouchardière C; Tougeron D; Jonchère V; Bennouna J; de Reynies A; Fléjou JF; Svrcek M; André T; Duval A
Ann Oncol; 2023 Aug; 34(8):703-713. PubMed ID: 37269904
[TBL] [Abstract][Full Text] [Related]
5. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
Colle R; Lonardi S; Cachanado M; Overman MJ; Elez E; Fakih M; Corti F; Jayachandran P; Svrcek M; Dardenne A; Cervantes B; Duval A; Cohen R; Pietrantonio F; André T
Oncologist; 2023 Sep; 28(9):771-779. PubMed ID: 37023721
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series.
Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H
Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555
[TBL] [Abstract][Full Text] [Related]
7. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract][Full Text] [Related]
8. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain.
Garcia-Carbonero R; González Astorga B; Vidal Tocino R; Contreras Toledo D; Pericay C; Fernández Montes A; Falcó E; González Cordero M; Reina Zoilo JJ; Alonso V; Rodríguez Salas N; Gil-Raga M; Santos C; Páez D; Anton-Pascual B; Aguilar F; Morales P
Clin Transl Oncol; 2024 Apr; 26(4):864-871. PubMed ID: 37651021
[TBL] [Abstract][Full Text] [Related]
9. A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair-deficient and microsatellite instability-high endometrial cancers.
Liu YL; Weigelt B
Cancer; 2024 May; 130(10):1733-1746. PubMed ID: 38422006
[TBL] [Abstract][Full Text] [Related]
10. The Day-To-Day Practice of MMR and MSI Assessment in Colorectal Adenocarcinoma: What We Know and What We Still Need to Explore.
Parente P; Grillo F; Vanoli A; Macciomei MC; Ambrosio MR; Scibetta N; Filippi E; Cataldo I; Baron L; Ingravallo G; Cazzato G; Melocchi L; Liserre B; Giordano C; Arborea G; Pilozzi E; Scapinello A; Aquilano MC; Gafà R; Battista S; Dal Santo L; Campora M; Carbone FG; Sartori C; Lazzi S; Hanspeter E; Angerilli V; Mastracci L; Fassan M
Dig Dis; 2023; 41(5):746-756. PubMed ID: 37231848
[TBL] [Abstract][Full Text] [Related]
11. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
[TBL] [Abstract][Full Text] [Related]
12. Deficient mismatch repair/microsatellite unstable colorectal cancer: therapeutic advances and questions.
Cervantes B; André T; Cohen R
Ther Adv Med Oncol; 2024; 16():17588359231170473. PubMed ID: 38205076
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms.
Xu Y; Liu K; Li C; Li M; Zhou X; Sun M; Zhang L; Wang S; Liu F; Xu Y
EBioMedicine; 2024 May; 103():105142. PubMed ID: 38691939
[TBL] [Abstract][Full Text] [Related]
14. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
Kim JH; Kim SY; Baek JY; Cha YJ; Ahn JB; Kim HS; Lee KW; Kim JW; Kim TY; Chang WJ; Park JO; Kim J; Kim JE; Hong YS; Kim YH; Kim TW
Cancer Res Treat; 2020 Oct; 52(4):1135-1144. PubMed ID: 32340084
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers.
Liu F; Zhong F; Wu H; Che K; Shi J; Wu N; Fu Y; Wang Y; Hu J; Qian X; Fan X; Wang W; Wei J
Oncologist; 2023 Mar; 28(3):e136-e144. PubMed ID: 36724040
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial DNA copy number plays opposing roles in T-lymphocyte infiltration of colorectal cancer based on mismatch repair status: new directions for immunotherapy?
Chen M; Liu H; Liang W; Huang P; Ye F; Cai Y; Liang Z; Xiong L; Kang L; Huang L
Br J Cancer; 2024 Mar; 130(5):798-807. PubMed ID: 38218920
[TBL] [Abstract][Full Text] [Related]
17. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.
Wang Q; Shen X; Chen G; Du J
Int J Cancer; 2023 Aug; 153(4):709-722. PubMed ID: 36752642
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future.
Sahin IH; Zhang J; Saridogan T; Gorantla V; Rhree J; Malhotra M; Thomas R; Hsu D; Saeed A
JCO Oncol Pract; 2023 May; 19(5):251-259. PubMed ID: 36862965
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability and mismatch repair protein deficiency: equal predictive markers?
Nádorvári ML; Lotz G; Kulka J; Kiss A; Tímár J
Pathol Oncol Res; 2024; 30():1611719. PubMed ID: 38655493
[TBL] [Abstract][Full Text] [Related]
20. A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
Moreau M; Alouani E; Flecchia C; Falcoz A; Gallois C; Auclin E; André T; Cohen R; Hollebecque A; Turpin A; Pernot S; Masson T; Di Fiore F; Dutherge M; Mazard T; Hautefeuille V; Van Laethem JL; De la Fouchardière C; Perkins G; Ben-Abdelghani M; Sclafani F; Aparicio T; Kim S; Vernerey D; Taieb J; Guimbaud R; Tougeron D
Eur J Cancer; 2024 May; 202():114033. PubMed ID: 38537314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]